A5103114228- PI3K/AKT/mTOR signaling in cancer
- Transgenic Plants and Applications
- Cancer Research and Treatments
- Toxin Mechanisms and Immunotoxins
- Microbial Inactivation Methods
- HER2/EGFR in Cancer Research
- Hippo pathway signaling and YAP/TAZ
- Chronic Lymphocytic Leukemia Research
- Inflammatory mediators and NSAID effects
- Cancer-related Molecular Pathways
- Cancer Mechanisms and Therapy
- Cancer-related gene regulation
- Genomics, phytochemicals, and oxidative stress
- Cancer, Lipids, and Metabolism
- Estrogen and related hormone effects
- Amino Acid Enzymes and Metabolism
- Epigenetics and DNA Methylation
Fudan University
2025
Xinxiang Medical University
2018-2022
The HER2-targeting antibody trastuzumab has shown effectiveness in treating HER2-positive breast and gastric cancers; however, its responses are limited. Currently, Nrf2 been deemed as a key transcription factor promoting cancer progression resistance by crosstalk with other proliferative signaling pathways. Brusatol novel inhibitor an efficacious safe drug candidate therapy. In this study, we firstly reported that brusatol exerted the growth-inhibitory effects on cells regressing Nrf2/HO-1...
Abstract Clear cell renal carcinoma (ccRCC) is the most lethal subtype of cancer, and its treatment options remain limited. Therefore, there an urgent need to discover therapeutic agents for ccRCC treatment. Here, we demonstrate that dimethyl fumarate (DMF), approved medication multiple sclerosis [1] psoriasis, can inhibit proliferation cells. Mechanistically, hepatocyte nuclear factor 1β (HNF1B), a transcription highly expressed in ccRCC, succinated by DMF at cysteine residues, leading...
Previously, we developed a novel EGFR-targeted antibody (denoted as Pan), which has superior antitumor activity against EGFR-overexpressed tumors. However, it shows marginal effect on the growth of esophageal cancers. Therefore, variable region Pan was fused to fragment Pseudomonas exotoxin A (PE38) create immunotoxin, denoted Ptoxin (PT). Results indicated that PT more effective compared with both KYSE-450 and KYSE-150 cancer cells, especially cells. Moreover, treatment induces regression...
The dual tyrosine kinase (EGFR/HER2) inhibitor lapatinib is currently used to clinically treat HER2-positive breast cancer. However, a majority of patients do not respond therapy within 6 months. Therefore, potentiating the anti-tumor effect by combination treatment has great potential overcome obstacle. Herein, we aim investigate activity in with brusatol and explore mechanism involved combinatorial treatment. Our findings revealed that Nrf2 potently enhanced against SK-BR-3, SK-OV-3 AU565...
Abstract Background D-mannose, an epimer of glucose, which is abundant in some fruits, such as cranberry, has been previously reported to inhibit urinary tract infection. In recent years, the potential function D-mannose broadened into regulation other inflammation diseases and cancer. It was that can increase reactive oxygen species (ROS) production, while IDH2 important for generation NADPH, crucial reducing factor. These findings prompted us determine whether regulate IDH2-mediated NADPH...
Dithiocarbamate has been reported to possess a potent antitumor efficacy against several types of cancer, such as ovarian breast cancer and hepatocellular carcinoma; however, only few studies have investigated its inhibitory effect on esophageal cancer. Dipyridylhydrazone dithiocarbamate (DpdtC) is novel derivative that was recently designed, synthesized evaluated in our previous study. In the present study, cell growth inhibition apoptosis induced by DpdtC were measured using CCK‑8 Annexin...